Shellfish Allergy Clinical Trial
— SWAPOfficial title:
Safety of Chitosan as Wine Fining Agent in Shrimp Allergic Patients
Chitosan, the main component of the exoskeletons of crustaceans, mollusks and cephalopods,
has been used as a fining agent in wines. However, its safety among patients allergic to
shellfish has never been evaluated.
Adult patients followed at the Allergy and Clinical Immunology Department who have been
diagnosed with anaphylaxis to shrimp will be invited to participate in the study.
Clinical data will be collected to ascertain for eligibility and written information will be
provided. After signing informed consent, included subjects will perform skin prick-to-prick
tests (PTP) with shrimp boiling water condensate and with fined and unfined wines. All will
perform double blind oral challenge with the fined and unfined wines during 1visit day; the
placebo (unfined wine) and active challenge (fined wine with chitosan) will be separated by
2 hours. Challenge protocol will be performed with successive increasing doses administered
in 4 steps at 15-minute intervals for a total of 100 mL. During the challenge signs and
symptoms will be monitored by a trained physician.
Results will be presented as negative or positive (defined by presence of symptoms and signs
of an allergic reaction).
Categorical data will be compared by chi-square test. P<0.05 will be considered
statistically significant.
| Status | Recruiting |
| Enrollment | 15 |
| Est. completion date | September 2014 |
| Est. primary completion date | July 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Aged above 18 and less than 65 years - Willing to comply with all study procedures and available for the duration of the study; - Diagnosed with shrimp allergy, based on clinical history, plus positive skin tests and/or positive IgE; - Previous anaphylactic reaction to shrimp; - Either sex and of any race - Provide signed and dated informed consent form Exclusion Criteria: - Dermatological disease which precludes or alters the results of skin tests - History of wine/alcohol intolerance - Acquired or hereditary immunodeficiency - Neoplasia - Psychiatric disease - FEV1<70% - Taking any systemic medication that might interfere with the study and that is not possible to withdraw, namely oral corticosteroids or immunomodulators in the last 4 weeks, or antihistamines in the last 10 days - Under beta-blockers or ACE inhibitors - Presence of any significant illness that could interfere with the study or alter its results or increase the risk of anaphylaxis, such as systemic mastocytosis - Pregnancy or lactation |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Portugal | Universidade de Aveiro | Aveiro | |
| Portugal | Serviço de Imunoalergologia Hospital São João | Porto |
| Lead Sponsor | Collaborator |
|---|---|
| Universidade do Porto | Aveiro University |
Portugal,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of participants with adverse events to a Double Blind Placebo Controlled Food Challenge with chitosan fined wine | Participants will be followed until one to two hours after the end of the Food Challenge, an expected average of 6 to 8 hours | Yes |